Super Copy of Great Power Technology

"No way, what kind of medicine is so powerful that it can cure advanced cancer? Are you kidding me?"

"Even the targeted cancer drugs produced by several major foreign pharmaceutical giants can only control the disease but not cure it. Ruida Pharmaceutical actually said that their new drug can cure early gastric cancer. It is unbelievable at first glance."

"Looking at the cases in the video and the films taken, it doesn't seem to be fake, but this is just one case, so it doesn't mean anything."

"How long has Ruida Pharmaceutical been established? Only a few months. They have developed such a miraculous anti-cancer targeted drug so quickly. Are they cheating?"

"Hey, I thought this was the only case, but there are more."

Yes, after Zheng Chongyuan's self-narration video, more than a dozen self-narration videos of gastric cancer patients were played. They were all volunteers in the first phase clinical trial of Gastric Cancer Killer. Their conditions were mild or severe, but after taking the medicine, they all had good effects. Two of the early gastric cancer patients even completely recovered their health after two weeks of treatment. After a stomach examination, no signs of gastric cancer were found, which was a miracle.

After playing all the videos, Lu Wanfeng took the podium again and said: "As you can see, our new drug Gastric Cancer Killer has a good effect on early, middle and late stage gastric cancer, and has a very significant ability to repair the diseased stomach, and can also inhibit the spread of cancer cells. The drug is as its name suggests, it is a real gastric cancer killer. At present, the second phase of clinical trials of the new drug is about to begin, and gastric cancer patients are welcome to sign up for clinical trials.

The second thing I want to announce is that our R&D team at Reda Pharmaceuticals has made a breakthrough in animal organ cloning. The team has successfully cultivated the stomach, kidneys and hearts of mice using cloning technology. These organs are structurally complete, fully functional and active. Next, our medical experts will transplant these organs back into mice through surgery to explore the technology of autologous cloning organ transplantation. Please watch a video recording of the experiment below. "

After that, the big screen behind him lit up again, showing a video of researchers collecting mouse somatic cells for directed organ cloning. The entire organ culture dish was made of glass, and the growth process of the mouse stomach, kidneys, and heart from nothing to something, from small to large, was clearly visible. Even after these organs grew to maturity, they continued to wriggle and beat in the culture dish, and it was obvious that they were all "alive" and could be used for organ transplantation.

Such a magical scene left all the reporters stunned. It was not until the end of the video that everyone came to their senses and raised their doubts.

"Mr. Lu, is this a real-life video or a special-effect scene you paid to create? Has organ cloning technology really evolved to this level?"

"Yes, if organ cloning technology is so easy, then it won't be long before we can clone human organs, right?"

"If all human organs can be cloned and produced in batches, many currently incurable diseases will have hope of being treated."

"The key is that when an organ is cloned, there will be no rejection when it is transplanted, which can greatly increase the survival rate of the organ."

"I always feel that this is all a bit too magical. Medical technology cannot progress so fast."

Lu Wanfeng pressed his hand, signaling everyone to be quiet, and then said: "I can guarantee with my personal reputation that the content played in the above video is true. At most, we selected some of the video materials and made some edits, and did not add any special effects. As for the human organ cloning that everyone mentioned, I can only say that this is the direction of our next research and development. There are still some difficulties to be overcome. As for when we can succeed, we don’t know."

Lu Wanfeng answered several questions from reporters and then announced the end of the press conference.

That afternoon, the content announced by Ruida Pharmaceuticals at the press conference appeared on the Internet and spread quickly. The experiment on animal organ cloning is not so bad. After all, only the cultivation of mouse organs has been completed. There is still a long way to go before the cultivation of human organs, and it is of little help to current patients. The successful development of gastric cancer killer is completely different. Gastric cancer is one of the most common cancers among the Chinese people. Nationwide, there are at least four or five hundred thousand new cases of gastric cancer each year, and most of them are in the middle and late stages. Even with traditional means of treatment such as surgery, radiotherapy and chemotherapy, the hope of cure is still slim, and it is not easy to even suppress the progression of the disease. Some targeted drugs imported from abroad have good therapeutic effects on certain types of gastric cancer, but their prices of tens of thousands of yuan are not affordable for every cancer patient.

Now, when these gastric cancer patients and their families heard that a domestic pharmaceutical company had successfully developed such a miraculous gastric cancer targeted drug, they went crazy. In just one afternoon, the official website of Ruida Pharmaceuticals received more than 10,000 applications for the second phase clinical trial of Gastric Cancer Killer. The two consultation telephone numbers published on the official website have become hotlines, with people calling 24 hours a day. Fortunately, these two calls were answered by artificial intelligence, so Ruida Pharmaceuticals employees did not have to answer the calls in person, which saved a lot of trouble.

"Mr. Qiao, we have received too many applications, far exceeding the scale of the Phase II clinical trial of new drugs. How should we deal with this?" Lu Wanfeng wiped the sweat from his forehead and asked Qiao Ruida.

"First, select those patients with advanced gastric cancer as volunteers for the Phase II clinical trial. As for those patients in the early and middle stages, they will not die in the short term anyway, so let them wait for a few more months. Maybe in a few months, our gastric cancer killer will pass the clinical test and be allowed to be marketed." Qiao Ruida said without turning his head, observing the differentiation and growth of somatic cells.

"There are about 2,000 to 3,000 patients with advanced gastric cancer. Do we need to conduct such a large-scale Phase II clinical trial? That would cost a lot more money."

"It doesn't matter if there are more volunteers. I have confidence in the efficacy of Gastric Cancer Killer. As for the high cost, let the patients pay for their own hospitalization expenses, and cancel the clinical subsidy. We will only provide free drugs and not take care of anything else." "Okay, it seems that this is the only way to do it. I hope the patients can understand."

After sending Lu Wanfeng away, Qiao Ruida continued to observe the cloning process of mouse kidneys and made detailed experimental records.

"Mr. Qiao, the organ cloning technology is now mature. It only takes about a week to cultivate a mouse kidney, and it can be mature and used for organ transplantation." A middle-aged man in a white coat stood next to Qiao Ruida and explained.

"It takes a week? That's not bad. By the way, how is the research on organ universality going? Is there any progress?" Qiao Ruida raised his head, stretched his waist, and asked.

"It's difficult. Mice, like humans, have obvious rejection reactions to organs that do not match their genes. We are currently trying to find the cause of the rejection reaction, but the mechanism of action is quite complicated and there has been no progress so far."

"Take your time. Life is the most amazing and complicated thing. It's not easy to figure out the principle of rejection. It seems that human organ cloning testing can only start with autologous cell cloning. How is the mouse organ transplantation surgery going? Has the success rate increased?"

Qiao Ruida came to Ruida Medical Laboratory to learn about the research and development progress of organ cloning technology and gastric transplant surgery. Grandma's condition has always been a thorn in his heart. Only when human organ cloning technology and gastric transplant surgery are fully mature, can it be possible to completely cure grandma's gastric cancer.

"Mr. Qiao, among the surgeries performed on mice, only kidney transplants are relatively mature. Basically, out of ten kidney transplants, at least nine can be successful. Gastric transplants are still in the initial exploratory stage. If one out of ten transplants is successful, it's considered good. As for heart transplants, we have performed more than thirty cases, but none have been successful so far."

"We should explore more, try more, and strive to master the technology of stomach and heart transplantation as soon as possible. Whether our cloned organs can be widely promoted depends on the success rate of organ transplantation. Only when the success rate is raised to more than 90% will a large number of patients come to us for customized organs, and we can make money and get our investment back."

Qiao Ruida also observed a mouse stomach transplant operation on site, pointed out several operating errors on the spot, and explained the reasons, which benefited several surgeons a lot. Qiao Ruida, a college student studying integrated circuits, actually instructed several medical experts to perform surgery on the spot. This scene seemed a bit funny, but the surgeons listened very seriously, as if they were facing their former mentors. The reason for this situation is that Qiao Ruida's ability is too terrifying. Including the gastric cancer nemesis and the current gastric and heart transplant surgery procedures and key points, they were all "developed" by him. Faced with such a monster like Qiao Ruida, these medical experts can only humbly ask for advice in front of him.

Qiao Ruida stayed in the Ruida Pharmaceutical Laboratory until the evening, then drove away and returned to the courtyard.

The two-day weekend holiday passed quickly, and Qiao Ruida and Du Qingqing returned to Peking University to continue their classes. Now it was the end of the semester, and the few subjects they had to take were about to have final exams. Qiao Ruida and Du Qingqing, as two top students, naturally had no problem taking these exams, and they got excellent grades without much effort. After the last exam of the semester, Du Qingqing walked around the campus with Qiao Ruida, holding a few books.

"Honey, the college has given me a place in graduate school. Do you think it is necessary for us to continue our studies in our current situation?" Du Qingqing asked in confusion. Now that they are wealthy and successful in their careers, it is worth considering whether they should continue to study for a master's degree.

"I also got a guaranteed place in graduate school. Academician Wang Chengye also invited me. As long as I nod, I can become his graduate student. Now I am a little undecided. With our current wealth and achievements, whether to study for a master's degree will not have much impact on our future work and life. But it would be a pity to give up the opportunity to become an academician's student. It represents not only more advanced knowledge, but also a huge network of people and resources. Wife, has any professor invited you to study for a master's degree?"

"Yes, there are more than one. One of them is a big shot who enjoys special government subsidies and serves as a special consultant in the Foreign Trade and Economic Cooperation Office. Many of the textbooks we study in our major were written by this big shot."

"What do you think? Do you plan to go to graduate school?"

"I don't know. In fact, I am quite satisfied with my current life. I run between school and company, and the pressure from work and study is not too great. Continuous learning gives me a great sense of accomplishment, and the work of the charity foundation makes me happy physically and mentally. I don't want to give up. But my mother has told me many times that we should get married and have children after graduation, which conflicts with graduate school. I don't know what to choose now."

Qiao Ruida hugged Du Qingqing in his arms and said, "Then let's study for a master's degree together. Anyway, with our intelligence and talents, we don't need to spend too much time on studying, and it won't affect our work in the company. As for getting married and having children, it won't conflict with studying for a master's degree. Many of the seniors in our school got married and had children during their graduate studies."

After the last professional course exam was completed, Qiao Ruida's undergraduate studies were completely over. There were no courses scheduled for the next semester, and the time was left for students to find jobs and do internships. They only needed to complete their graduation thesis on time to successfully obtain their graduation certificates and degree certificates. Qiao Ruida and Du Qingqing now have their own companies and jobs, so of course they don't have to look for internships anymore. As for the graduation thesis, Qiao Ruida plans to do a big job, which is to start with a self-developed instruction set and design a new graphene processor, mainly for artificial intelligence computing.

With the development of computer technology and network technology, artificial intelligence technology has emerged and its application scope is getting wider and wider. Artificial intelligence applications such as intelligent driving, automatic speech recognition, intelligent translation, intelligent image generation, etc. are emerging in an endless stream. However, with the continuous development of artificial intelligence technology, higher and higher requirements are placed on hardware computing power. Traditional X86 architecture or ARM architecture processors have become increasingly incapable. In order to resolve this contradiction, some companies focus on GPU-assisted computing, while some companies choose to develop dedicated AI modules to increase the AI ​​computing power of the processor. What Qiao Ruida has to do now is to develop a dedicated chip for artificial intelligence computing to run applications such as some large artificial intelligence models.

The various processor chips that Qiao Ruida had previously "developed" were all based on a certain mature chip in the future as a reference, and on this basis, they were modified and adapted. However, Qiao Ruida did not intend to do so for this graduation thesis. (End of this chapter)